Table 1.
Baseline characteristics of T2DM patients with rs1800504.
| Variable | Coronary heart disease | Non-coronary heart disease | Total | |||
|---|---|---|---|---|---|---|
| CC+CT | TT | CC+CT | TT | CC+CT | TT | |
| (n = 222) | (n = 26) | (n = 542) | (n = 134) | (n = 770) | (n = 160) | |
| Age (year), mean (SD) | 64.6 (9.51) | 67.6 (8.25) | 56.0 (11.3) | 57.8 (10.3) | 58.5 (11.5) | 59.4 (10.6) |
| Male, n (%) | 124 (55.9) | 14 (53.8) | 323 (59.6) | 78 (58.2) | 451 (58.6) | 90 (56.3) |
| Smoking history, n (%) | 72 (36.0) | 10 (40.0) | 189 (37.1) | 40 (31.5) | 264 (37.0) | 50 (32.9) |
| Drinking history, n (%) | 63 (31.7) | 7 (29.2) | 146 (28.7) | 35 (27.3) | 211 (29.6) | 42 (27.6) |
| History of cardiovascular disease, n (%) | 87 (39.7) | 14 (56.0) | 19 (3.6) | 5 (3.8) | 106 (14.0) | 19 (12.1) |
| History of cerebrovascular disease, n (%) | 34 (15.5) | 1 (4.0) | 37 (6.9) | 6 (4.5) | 73 (9.6) | 7 (4.5) |
| BMI (kg/m2), mean (SD)* | 24.5 (3.24) | 23.7 (3.30) | 24.2 (4.30) | 23.4 (3.67) | 24.3 (4.01) | 23.5 (3.60) |
| Waist-hip ratio, mean (SD) | 0.95 (0.07) | 0.95 (0.06) | 0.96 (0.01) | 0.95 (0.37) | 0.95 (0.31) | 0.93 (0.06) |
| Vitamin D deficiency rickets, n (%) | 138 (62.2) | 13 (50.0) | 352 (64.9) | 86 (64.2) | 494 (64.2) | 99 (61.9) |
| Fasting blood glucose (mmol/l), mean (SD) | 7.36 (2.85) | 8.32 (2.31) | 7.70 (2.92) | 7.52 (2.59) | 7.61 (2.91) | 7.65 (2.56) |
| GLU-60 (mmol/L), mean (SD) | 11.9 (3.85) | 11.2 (3.85) | 12.1 (3.74) | 10.9 (3.39) | 12.0 (3.74) | 10.9 (3.42) |
| GLU-120 (mmol/L), mean (SD) | 12.3 (4.07) | 13.0 (4.48) | 12.3 (4.24) | 12.4 (4.09) | 12.3 (4.18) | 12.5 (4.14) |
| Cpst-0 (pmol/L), mean (SD) | 499.1 (471.2) | 440.5 (247.1) | 418.8 (322.5) | 375.3 (221.1) | 441.3 (370.8) | 386.0 (225.8) |
| Cpst-60 (pmol/L), mean (SD) | 819.8 (483.0) | 772.4 (435.7) | 714.0 (531.7) | 603.9 (408.5) | 748.7 (517.5) | 634.9 (412.9) |
| Cpst-120 (pmol/L), mean (SD) | 1,059.5 (840.0) | 945.7 (552.2) | 920.3 (681.9) | 1,100.3 (903.5) | 961.1 (733.4) | 1,073.4 (852.9) |
| AST (IU/L), mean (SD) | 23.5 (34.4) | 19.7 (7.8) | 21.6 (15.3) | 21.4 (14.2) | 22.1 (22.5) | 21.1 (13.4) |
| ALT (IU/L), mean (SD) | 23.6 (46.1) | 17.0 (6.3) | 22.8 (22.1) | 22.1 (19.5) | 23.0 (30.9) | 21.3 (18.2) |
| CREA (μmol/l), mean (SD) | 102.4 (101.2) | 82.1 (44.4) | 84.3 (77.8) | 78.4 (55.7) | 89.6 (85.4) | 79.0 (53.9) |
| TBA (μmol/L), mean (SD) | 5.5 (5.5) | 8.1 (9.1) | 5.47 (7.34) | 6.15 (7.87) | 5.47 (6.80) | 6.47 (8.08) |
| eGFR (ml/min/1.73 m2), mean (SD) | 80.6 (32.7) | 82.8 (40.5) | 98.5 (34.2) | 96.5 (32.3) | 93.7 (34.6) | 95.0 (33.3) |
| Medical treatment | ||||||
| Insulin drugs, n (%) | 186 (89.9) | 21 (95.5) | 403 (87.6) | 97 (87.4) | 594 (88.4) | 118 (88.7) |
| Biguanides, n (%) | 85 (38.3) | 11 (42.3) | 267 (49.3) | 75 (56.0) | 355 (46.1) | 86 (53.8) |
| Insulin agonist, n (%) | 9 (4.1) | 2 (7.7) | 34 (6.3) | 11 (8.2) | 43 (5.6) | 13 (8.1) |
| DPP-4 inhibitor, n (%) | 91 (41.0) | 9 (34.6) | 245 (45.2) | 51 (38.1) | 339 (44.0) | 60 (37.5) |
| GLP-1 receptor agonist, n (%) | 5 (2.3) | 0 (0.0) | 19 (3.5) | 2 (1.5) | 24 (3.1) | 2 (1.3) |
| SGLT-2 inhibitor, n (%) | 9 (4.1) | 0 (0.0) | 21 (3.9) | 6 (4.5) | 32 (4.2) | 6 (3.8) |
| Lipid-lowering agents, n (%) | 188 (84.7) | 21 (80.8) | 363 (67.0) | 86 (64.2) | 556 (72.2) | 107 (66.9) |
| Glucosidase inhibitor, n (%) | 119 (53.6) | 18 (69.2) | 305 (56.3) | 79 (59.0) | 428 (55.6) | 97 (60.6) |
| Calcium Dobesilate, n (%) | 108 (49.1) | 13 (50.0) | 253 (46.8) | 55 (41.0) | 366 (47.7) | 68 (42.5) |
| β-receptor blocker, n (%) | 81 (36.5) | 12 (46.2) | 64 (11.8) | 13 (9.7) | 145 (18.8) | 25 (15.6) |
| Calcium antagonists, n (%) | 109 (49.1) | 11 (42.3) | 178 (32.8) | 43 (32.1) | 290 (37.7) | 54 (33.8) |
| ACEI/ARB, n (%) | 116 (52.3) | 17 (65.4) | 198 (36.5) | 48 (35.8) | 317 (41.2) | 65 (40.6) |
BMI, body mass index; GLU, glucose; Cpst, the secretion rate of C-peptide; AST, aspartate aminotransferase; ALT,alanine aminotransferase; CREA, creatinine; TBA, total bile acids; eGFR, glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
*
p-value of any one of Coronary heart disease, Non-coronary heart disease and Total group is < 0.05.